% study characteristics
% need to have `\\` after caption entries, otherwise compiler hangs
% reduced font size, expanded margins, remove page numbers, footer & headers - this reduces to 3 pages instead of 4-5
% sum of n (model) = 4599; sum of relapses = 228. 

{
\newgeometry{left=1.5cm, right=1.5cm, top=2cm, bottom=1.5cm}
\captionsetup{width=1\textheight, font=scriptsize, skip=7pt}

\begin{landscape}
    % \singlespacing
    \pagestyle{empty}
    \scriptsize
    \begin{ThreePartTable}
        \begin{TableNotes}
            \item[1] Study name is composed of the lead author and year of publication or most recent protocol.
            \item[2] Miltefosine dosing (i) $\geq$12 years and $\geq$25kg: 50mg BD; (ii) $\geq$12 years and $<$25kg: 50mg OD; (iii) $<$12 years and $<$25kg: 2.5mg/kg/day.
            \item[3] Dosing in $<$12 years and $<$25kg: in divded doses
            \item[4] Contributed number of participants from KAMRC site only.
            \item[5] ABD arm not presented in publication.
            \item[6] Dosing in $<$12 years and $<$25kg: not further described.
            \item[7] Dosing not further described.
            \item[8] SSG route of administration (IV vs IM) not specified.


        \end{TableNotes}

        \begin{longtable}[c]{L{1.5cm} L{3.5cm} L{1.3cm} L{2.5cm} L{2.5cm} L{2.5cm} L{3cm} L{1.5cm} L{1cm} L{1cm} L{1.3cm}}
            \caption{Key characteristics of included studies, ordered by lead author and year of publication/protocol. Where information not presented in the publication, information is extracted from the study protocol. -: not reported; ABLE: Amphotericin B lipid emulsion (Bharat Serum and Vaccines Ltd.); alt.: alternative; ABD: Amphotericin B deoxycholate; BD: twice daily (bis die); BMGF: Bill and Melinda Gates Foundation; BPKIHS: B.P. Koirala Institute of Health Sciences; D: Day(s); EC: European Commission; Govt.: Government; ICMR: Indian Council of Medical Research; IM: Intramuscular; KAMRC: Kala-azar Medical Research Center; LAMB: Liposomal amphotericin B (Gilead formulation unless otherwise specified); MF: Miltefosine; mg/kg: milligrams per kilogram; NCVBDC: National Center for Vector Borne Diseases Control; OD: once daily (omni die); P: Publication; PATH: Program for Appropriate Technology in Health; PO: per os (oral) PM: Paromomycin; Pr: Protocol; Ref: Reference; RMRIMS: Rajendra Memorial Research Institute of Medical Sciences; SSG: Sodium stibogluconate; TDR: UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; UN: United Nations; WHO: World Health Organization\label{tab:isc_study}} \\
            \toprule
            Study\tnote{1}                                  & Title                                                                                                                                                                                                                       & Journal                  & Sponsor/funding                                                                      & Location(s)                                       & Study design                                                                       & Study arm(s)                                                                                                                                                                                                      & Age (years) & Study period & n (model)    & Relapses (\%)                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \midrule
            \endfirsthead

            \caption[]{continued}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \\
            \toprule
            Study\tnote{1}                                  & Title                                                                                                                                                                                                                       & Journal                  & Sponsor/funding                                                                      & Location(s)                                       & Study design                                                                       & Study arm(s)                                                                                                                                                                                                      & Age (years) & Study period & n (model)    & Relapses (\%)                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \midrule
            \endhead

            \multicolumn{11}{r}{\textit{continued on next page}}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   \\
            \endfoot

            \insertTableNotes
            \endlastfoot

            Bhattacharya 2007\cite{bhattacharya2007}        & Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis                                                                                                                                             & J Infect Dis             & ICMR                                                                                 & 13 locations in Bihar, India (outpatient setting) & Open label; phase 4; safety/efficacy                                               & (1) MF, PO, 28D, dosed according to age and weight\tnote{2,3}                                                                                                                                                     & 2--65       & 2002--2004   & 352\tnote{4} & 22 (6.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\ \midrule
            Chakraborty 2008\cite{chakraborty2008}          & Human placental extract offers protection against experimental visceral leishmaniasis: a pilot study for a phase-I clinical trial                                                                                           & Am J Trop Med Hyg        & Indian Council of Scientific and Industrial Research; Albert David Ltd.              & KAMRC, Muzaffarpur, India                         & ``Pre-phase 1''; pilot/preliminary                                                 & (1) Human placental extract, 2.06mg, IM, single dose; (2) ABD, 1mg/kg, IV, alt. days for 30D\tnote{5}                                                                                                             & $\geq$5     & 2003--2005   & 6            & 0 (0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \\ \midrule
            Das 2009\cite{das2009}                          & A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India & Ther Clin Risk Manag     & -                                                                                    & RMRIMS, Patna, India                              & Randomised; open label; efficacy                                                   & (1) ABD, 1mg/kg, IV, alt. days for 30D; (2) pentamidine, 4mg/kg, IM, alt. days for 30D                                                                                                                            & 6--60       & 2002         & 73           & 5 (6.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Koirala 2003                                    & Phase IV trial of miltefosine in the treatment of visceral leishmaniasis                                                                                                                                                    & Protocol only            & -                                                                                    & BPKIHS, Dharan, Nepal                             & Open label; phase 4; safety/efficacy                                               & (1) MF, PO, 28D, dosed according to age and weight\tnote{2,3}                                                                                                                                                     & 2--65       & 2003--2004   & 116          & 12 (10.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   \\ \midrule
            Pandey 2016\cite{pandey2016}                    & Pharmacovigilance of miltefosine in treatment of visceral leishmaniasis in endemic areas of Bihar                                                                                                                           & Am J Trop Med Hyg        & NCVBDC, Govt. of India; World Bank                                                   & 4 locations in Bihar, India                       & Open label; safety/efficacy                                                        & (1) MF, PO, 28D, dosed according to age and weight\tnote{2,6}                                                                                                                                                     & 6--70       & 2012--2015   & 600          & 45 (7.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\ \midrule
            Pandey 2017\cite{pandey2017}                    & Efficacy and safety of liposomal amphotericin B for visceral leishmaniasis in children and adolescents at a tertiary care center in Bihar, India                                                                            & Am J Trop  Med Hyg       & -                                                                                    & RMRIMS, Patna, India                              & Open label; safety/efficacy                                                        & (1) LAMB, 10mg/kg, IV, single dose                                                                                                                                                                                & $<$15       & 2014--2016   & 100          & 2 (2.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Rijal 2003\cite{rijal2003}                      & Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline                                                                     & Trans R Soc Trop Med Hyg & WHO, Geneva University Hospital; Novartis Foundation                                 & BPKIHS, Dharan, Nepal                             & Non-randomised; efficacy                                                           & SSG, 20mg/kg, IV/IM\tnote{7}, OD, 30D, extended to 40D if positive aspirate at 30D. Either (1) in hospital or (2) first 5--7 days in hospital;                                                                    & All         & 2000--2001   & 102          & 1 (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Rijal 2010(A)\cite{rijal2010a}                  & Efficacy and safety of liposomal amphotericin B in Nepalese patients with visceral leishmaniasis                                                                                                                            & Protocol only            & TDR                                                                                  & BPKIHS, Dharan, Nepal                             & Phase 2/3; safety/efficacy                                                         & (1) LAMB, 3mg/kg, IV, OD, D1-5 (21mg/kg total dose)                                                                                                                                                               & 12--65      & 2010--2011   & 32           & 1 (3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Rijal 2010(B)\cite{rijal2010b}                  & Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal                                                                                                           & Trans R Soc Trop Med Hyg & EC (5th Framework Programme)                                                         & BPKIHS, Dharan, Nepal                             & Prospective cohort                                                                 & (1) SSG, 20mg/kg, IV/IM\tnote{7}, OD, 30D                                                                                                                                                                         & -           & 2001--2003   & 178          & 1 (0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Sundar 2007\cite{sundar2007a,sundar2005prot}    & Injectable paromomycin for visceral leishmaniasis in India                                                                                                                                                                  & N Engl J Med             & PATH (including UN, BMGF, TDR)                                                       & 4 locations in Bihar, India                       & Randomised; open label; phase 3; non-inferiority; safety/efficacy                  & (1) PM, 15mg/kg, IM, OD, 21D; (2) ABD, 1mg/kg, IV, alt. days for 30D                                                                                                                                              & 5--55       & 2003--2004   & 250\tnote{4} & 4 (1.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Sundar 2008(A)\cite{sundar2008protC,sundar2008} & New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine                                                                                     & Clin Infect Dis          & Banaras Hindu University                                                             & KAMRC, Muzaffarpur, India                         & Partially randomised; open label; phase 2; non-comparative; sequential; triangular & LAMB, 5mg/kg, IV, single dose, either (1) alone, or (2,3,4) in combination with MF, 50mg, PO, BD, D2--9, D2--11, or D2--15; and (5) combination of LAMB, 3.75mg/kg, IV, single dose, and MF, 50mg, PO, BD, D2--15 & $\geq$12    & 2006--2007   & 225          & 7 (3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Sundar 2008(B)\cite{sundar2008B}                & Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian kala-azar                                                                                                                              & Trop Med Int Health      & Bharat Serum and Vaccines Ltd.                                                       & KAMRC, Muzaffarpur, India                         & Non-randomised; non-comparative; open label; phase 2; safety/efficacy              & ABLE, IV, OD, 3D at (1) 5mg/kg (2) 4mg/kg, or (3) 3mg/kg                                                                                                                                                          & 12--65      & 2004--2005   & 45           & 4 (8.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Sundar 2009\cite{sundar2008protB, sundar2009}   & Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment                                                                                                                           & Clin Infect Dis          & Banaras Hindu University                                                             & KAMRC, Muzaffarpur, India                         & Randomised; open label; phase 3; safety/efficacy                                   & PM, 15mg/kg, IM, OD, either (1) 14D or (2) 21D                                                                                                                                                                    & 5--55       & 2007--2008   & 307          & 26 (8.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\ \midrule
            Sundar 2010\cite{sundar2008protA, sundar2010}   & Single-dose liposomal amphotericin B for visceral leishmaniasis in India                                                                                                                                                    & N Engl J Med             & Banaras Hindu University                                                             & KAMRC, Muzaffarpur, India                         & Randomised; open label; phase 3; safety/efficacy                                   & (1) ABD, 1mg/kg, IV, alt. days for 30D; (2) LAMB, 10mg/kg, IV, single dose                                                                                                                                        & 2--65       & 2008--2009   & 412          & 14 (3.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\ \midrule
            Sundar 2011\cite{sundar2006prot,sundar2011}     & Ambisome plus miltefosine for Indian patients with kala-azar                                                                                                                                                                & Trans R Soc Trop Med Hyg & Banaras Hindu University                                                             & KAMRC, Muzaffarpur; RMRIMS, Patna, India          & Open label; phase 2; safety/efficacy                                               & (1) LAMB, 5mg/kg, IV, single dose, with MF, 2.5mg/kg/day, PO, D2-D15\tnote{8}                                                                                                                                     & 2--65       & 2007--2009   & 128          & 5 (3.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Sundar 2012\cite{sundar2012}                    & Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use                                                                                                                           & Clin Infect Dis          & EC (Kaladrug-R); Sitaram Memorial Trust                                              & KAMRC, Muzaffarpur, India                         & Open label; safety/efficacy                                                        & (1) MF, PO, 28D, dosed according to age and weight\tnote{2, 3}                                                                                                                                                    & 6--70       & 2009--2010   & 571          & 34 (6.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\ \midrule
            Sundar 2014\cite{sundar2009prot, sundar2014}    & Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomised, open-label study                                                                  & PLoS Negl Trop Dis       & Bharat Serums and Vaccines Ltd; Department of Science and Technology, Govt. of India & 4 locations in Bihar, India.                      & Randomised; open label; phase 3; safety/efficacy                                   & (1) LAMB, 15mg/kg, IV, single dose; (2) ABLE, 15mg/kg, IV, single dose                                                                                                                                            & 5--65       & 2009--2011   & 144\tnote{4} & 9 (6.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \\ \midrule
            Sundar 2015\cite{sundar2011prot,sundar2015}     & Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: A phase 2 study                                                                                                          & Am J Trop Med Hyg        & Lifecare Innovations; Department of Science and Technology, Govt. of India           & KAMRC, Muzaffarpur, India                         & Non-randomised; non-comparative; open label; phase 2; safety/efficacy              & LAMB (Lifecare Innovations), IV, single dose (1) 10mg/kg or (2) 15mg/kg                                                                                                                                           & 12--60      & 2012--2013   & 30           & 3 (10.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\ \midrule
            Sundar 2019\cite{sundar2012prot,sundar2019}     & Effectiveness of single-dose liposomal amphotericin B in visceral leishmaniasis in Bihar                                                                                                                                    & Am J Trop Med Hyg        & Banaras Hindu University                                                             & KAMRC, Muzaffarpur, India                         & Observational; efficacy                                                            & (1) LAMB, 10mg/kg, IV, single dose                                                                                                                                                                                & All         & 2013--2017   & 928          & 33 (3.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \\ \bottomrule
        \end{longtable}
    \end{ThreePartTable}
\end{landscape}
}
\pagestyle{fancy}
\restoregeometry